NASDAQ:SVRA

Savara - SVRA Stock Forecast, Price & News

$1.58

-0.06 (-3.66%)

(As of 11/30/2022 12:00 AM ET)

Add

Compare

Today's Range: $1.51
▼
$1.66
50-Day Range: $1.11
▼
$1.64
52-Week Range: $1.02
▼
$1.91

Volume: 98,729 shs
Average Volume: 127,319 shs
Market Capitalization: $180.18 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $3.00

Savara MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 89.9% Upside
$3.00 Price Target
Short Interest: Healthy
0.77% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.74
Based on 2 Articles This Week
Insider Trading: Acquiring Shares
$149,660 Bought Last Quarter
Proj. Earnings Growth: Decreasing
From ($0.26) to ($0.28) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.10 out of 5 stars

Medical Sector

599th out of 1,043 stocks

Pharmaceutical Preparations Industry

290th out of 510 stocks

3.5

Analyst's Opinion

Consensus Rating
Savara has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $3.00, Savara has a forecasted upside of 89.9% from its current price of $1.58.
Amount of Analyst Coverage
Savara has only been the subject of 1 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.77% of the float of Savara has been sold short.
Short Interest Ratio / Days to Cover
Savara has a short interest ratio ("days to cover") of 5.4.
Change versus previous month
Short interest in Savara has recently decreased by 0.95%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Savara does not currently pay a dividend.
Dividend Growth
Savara does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for SVRA.

2.1

News and Social Media Coverage

News Sentiment
Savara has a news sentiment score of 0.74. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Savara this week, compared to 1 article on an average week.
MarketBeat Follows
Only 1 people have added Savara to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Savara insiders have bought more of their company's stock than they have sold. Specifically, they have bought $149,660.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 3.57% of the stock of Savara is held by insiders.
Percentage Held by Institutions
67.69% of the stock of Savara is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Savara are expected to decrease in the coming year, from ($0.26) to ($0.28) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Savara is -6.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Savara is -6.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Savara has a P/B Ratio of 1.55. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Savara (NASDAQ:SVRA) Stock

Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.

Receive SVRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Savara and its competitors with MarketBeat's FREE daily newsletter.

SVRA Stock News Headlines

November 23, 2022 | americanbankingnews.com

David A. Ramsay Acquires 25,005 Shares of Savara Inc (NASDAQ:SVRA) Stock

November 23, 2022 | americanbankingnews.com

David A. Ramsay Acquires 8,900 Shares of Savara Inc (NASDAQ:SVRA) Stock

November 22, 2022 | finance.yahoo.com

Savara Announces New Employment Inducement Grant

November 10, 2022 | finance.yahoo.com

Savara Reports Third Quarter 2022 Financial Results and Provides Business Update

November 9, 2022 | finance.yahoo.com

Savara to Participate in Three Upcoming Investor Conferences

October 22, 2022 | reuters.com

SVRA.N - Savara Inc | Stock Price & Latest News | Reuters

October 20, 2022 | globenewswire.com

Bionano Genomics Announces Presentation of OGM Utility Across Key Applications at American Society of Human Genetics (ASHG) Annual Meeting - GlobeNewswire

October 17, 2022 | finance.yahoo.com

Peptide Antibiotics Market Research Report by Type, Disease, Route of Administration, Distribution Channel, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19 - Yahoo Finance

October 5, 2022 | finance.yahoo.com

Savara Inc. (SVRA)

October 3, 2022 | reuters.com

SVRA.OQ - Savara Inc | Stock Price & Latest News | Reuters

September 28, 2022 | benzinga.com

INVESTIGATION ALERT: Fields Kupka & Shukurov LLP Is Investigating Savara Inc. for Potential Breach of Fid - Benzinga

September 28, 2022 | benzinga.com

Goodwill Central Texas Announces Rob Neville as President and CEO - Savara (NASDAQ:SVRA) - Benzinga

September 14, 2022 | reuters.com

Philip Morris appoints two former U.S. FDA officials to key roles - Reuters

September 8, 2022 | forbes.com

James Bond's Tastes: 'For Your Eyes Only' - Forbes

September 7, 2022 | nasdaq.com

The Independent Director of Savara Inc. (NASDAQ:SVRA), David Ramsay, Just Bought 6.2% More Shares - Nasdaq

September 7, 2022 | finance.yahoo.com

Savara Presented Data at the European Respiratory Society (ERS) International Congress 2022 - Yahoo Finance

September 6, 2022 | businesswire.com

Savara Presented Data at the European Respiratory Society (ERS) International Congress 2022 - Business Wire

September 6, 2022 | finance.yahoo.com

Savara Presented Data at the European Respiratory Society (ERS) International Congress 2022

September 3, 2022 | finance.yahoo.com

Trade Alert: The Independent Director Of Savara Inc. (NASDAQ:SVRA), David Ramsay, Has Just Spent US$142k Buying 6.2% More Shares

September 1, 2022 | finance.yahoo.com

Savara to Present at H.C. Wainwright 24th Annual Global Investment Conference

August 26, 2022 | nasdaq.com

Health Care Sector Update for 08/25/2022: XLV, ERYP, INVO, SVRA - Nasdaq

August 26, 2022 | seekingalpha.com

Savara's chief medical officer resigns - Seeking Alpha

August 26, 2022 | finance.yahoo.com

Savara Announces Resignation of Chief Medical Officer

August 25, 2022 | businesswire.com

Savara Awarded Promising Innovative Medicine (PIM) Designation in the United Kingdom (UK) for Molgramostim Nebulizer Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) - Business Wire

August 25, 2022 | finance.yahoo.com

Savara Awarded Promising Innovative Medicine (PIM) Designation in the United Kingdom (UK) for Molgramostim Nebulizer Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive SVRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Savara and its competitors with MarketBeat's FREE daily newsletter.

SVRA Company Calendar

Last Earnings: 11/10/2022
Today: 12/01/2022
Fiscal Year End: 12/31/2022
Next Earnings (Estimated): 3/29/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:SVRA
Previous Symbol: AMEX:ANX
CUSIP: N/A
CIK: 1160308
Web: www.savarapharma.com
Phone: 512-614-1848
Fax: 858-552-0876
Employees: N/A
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $3.00
High Stock Price Forecast: $3.00
Low Stock Price Forecast: $3.00
Forecasted Upside/Downside: +89.9%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.25)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-43,010,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -29.86%
Return on Assets: -24.20%

Debt

Debt-to-Equity Ratio: 0.22
Current Ratio: 26.55
Quick Ratio: 26.55

Sales & Book Value

Annual Sales: $260,000.00
Price / Sales: 693.01
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.02 per share
Price / Book: 1.55

Miscellaneous

Outstanding Shares: 114,040,000
Free Float: 109,973,000
Market Cap: $180.18 million
Optionable: Optionable
Beta: 0.67

Key Executives

Robert N. Neville (Age 51)
Chairman of the Board, Chief Executive Officer

Taneli Jouhikainen (Age 51)
President, Chief Operating Officer

David L. Lowrance (Age 50)
Chief Financial Officer

Nevan C. Elam (Age 49)
Independent Director

Richard J. Hawkins (Age 68)
Independent Director

Joseph S. McCracken Ph.D. (Age 64)
Independent Director

Matthew Pauls J.D. (Age 46)
Independent Director

Yuri Pikover (Age 56)
Independent Director

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

SVRA Stock - Frequently Asked Questions

Should I buy or sell Savara stock right now?: 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Savara in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" SVRA shares.
View SVRA analyst ratings or view top-rated stocks.
What is Savara's stock price forecast for 2023?: 1 brokerages have issued 12-month target prices for Savara's shares. Their SVRA share price forecasts range from $3.00 to $3.00. On average, they anticipate the company's stock price to reach $3.00 in the next year. This suggests a possible upside of 89.9% from the stock's current price.
View analysts price targets for SVRA or view top-rated stocks among Wall Street analysts.
How have SVRA shares performed in 2022?: Savara's stock was trading at $1.24 on January 1st, 2022. Since then, SVRA shares have increased by 27.4% and is now trading at $1.58.
View the best growth stocks for 2022 here.
When is Savara's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 29th 2023.
View our SVRA earnings forecast.
How were Savara's earnings last quarter?: Savara Inc (NASDAQ:SVRA) released its quarterly earnings results on Thursday, November, 10th. The company reported ($0.07) earnings per share for the quarter, meeting the consensus estimate of ($0.07).

What other stocks do shareholders of Savara own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Savara investors own include BioLineRx (BLRX), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), CEL-SCI (CVM), Geron (GERN), Inovio Pharmaceuticals (INO), T2 Biosystems (TTOO), Verastem (VSTM), Agile Therapeutics (AGRX) and Corbus Pharmaceuticals (CRBP).
What is Savara's stock symbol?: Savara trades on the NASDAQ under the ticker symbol "SVRA."
Who are Savara's major shareholders?: Savara's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Farallon Capital Management LLC (8.69%), VR Adviser LLC (3.99%), AXA S.A. (3.00%), Kayne Anderson Rudnick Investment Management LLC (1.07%), UBS Oconnor LLC (0.33%) and Connor Clark & Lunn Investment Management Ltd. (0.15%). Insiders that own company stock include Badrul A Chowdhury, David A Ramsay, David L Lowrance, Joseph S Mccracken and Matthew Pauls.
View institutional ownership trends.
How do I buy shares of Savara?: Shares of SVRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Savara's stock price today?: One share of SVRA stock can currently be purchased for approximately $1.58.
How much money does Savara make?: Savara (NASDAQ:SVRA) has a market capitalization of $180.19 million and generates $260,000.00 in revenue each year. The company earns $-43,010,000.00 in net income (profit) each year or ($0.25) on an earnings per share basis.
How can I contact Savara?: Savara's mailing address is 6836 Bee Cave Road Building III Suite 200, AUSTIN TX, 78746. The official website for the company is www.savarapharma.com. The company can be reached via phone at 512-614-1848, via email at ir@savarapharma.com, or via fax at 858-552-0876.

This page (NASDAQ:SVRA) was last updated on 12/1/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial